Sarepta Therapeutics (SRPT)
(Delayed Data from NSDQ)
$15.91 USD
-0.51 (-3.11%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $15.95 +0.04 (0.25%) 7:58 PM ET
4-Sell of 5 4
C Value F Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
SRPT 15.91 -0.51(-3.11%)
Will SRPT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SRPT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SRPT
Will Insmed (INSM) Report Negative Earnings Next Week? What You Should Know
Sarepta Therapeutics (SRPT) to Report Q2 Results: Wall Street Expects Earnings Growth
SRPT: What are Zacks experts saying now?
Zacks Private Portfolio Services
SRPT Slides on Voluntary US Elevidys Shipment Pause Amid Scrutiny
SRPT Down After Third Death in Muscular Dystrophy Gene Therapy Program
SRPT Stock Soars on Unveiling New Restructuring Plan, Pipeline Pivots
Other News for SRPT
Notable analyst calls this week: Nike, Microsoft and Sarepta among top picks
EXCLUSIVE: July's 20 Most-Searched Tickers On Benzinga Pro — Where Do Opendoor, Nvidia, Apple Stock Rank?
Buy/Sell: Wall Street's top 10 stock calls this week
SRPT September 12th Options Begin Trading
Sarepta Therapeutics to Announce Second Quarter 2025 Financial Results | SRPT Stock News